Canditral Warnings

If clinical signs and symptoms consistent with liver disease develop that may be attributable to Itraconazole, CANDITRAL should be discontinued.
Coadministration of terfenadine with Itraconazole is contraindicated. Rare cases of serious cardiovascular adverse effects including death, ventricular tachycardia and torsades de pointes have been observed in patients taking Itraconazole concomitantly with terfenadine due to increased terfenadine concentrations induced by Itraconazole.
Pharmacokinetic data indicate that another oral antifungal. Ketoconazole inhibits the metabolism of astemizole, resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals. In vitro data suggest that Itraconazole, when compared to Ketoconazole, has a less pronounced effect on the biotransformation system responsible for the metabolism of astemizole. Based on the chemical resemblance of Itraconazole and Ketoconazole, Coadministration of astemizole with itraconazole is contraindicated.